Medical Doctor Program year 2024 Source: CMS Open Payments, 2026 publication

Christopher Lowther

Dermatology Cody, WY Medical Doctor

NPI 1790749836 CMS profile 471406

802 Gerrans Ave, Cody, WY 82414

Open in the dashboard

General payments

$19

1 record reported · program year 2024

Research payments

$0

Paid to them · None reported · program year 2024

Ownership & investment interest

$0

None reported

Through program year 2024, Christopher Lowther of Cody, WY is reported in the CMS Open Payments database as having received $19 across 1 general payment and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 1st percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2024 General $19 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Lowther
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Christopher Lowther were reported at $0. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Christopher Lowther Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $0 $514 $143–$1,391 $149
2023 $0 $607 $159–$1,674 $160
2024 $19 $751 $204–$1,903 $164
2025 $0 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program year 2024
  1. Dermavant Sciences, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program year 2024
  1. Food and Beverage $19 1 payment
Products named General payments · program year 2024
  1. VTAMA $19 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

628

Median for Internal Medicine: 777

Drug cost

$20,395

Median for Internal Medicine: $73,373

Branded share of claims

15.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 13 $11,409
Nifedipine Er Nifedipine Brand 26 $1,312
Ketoconazole Generic 44 $1,009
Warfarin Sodium Generic 16 $931
Labetalol Hcl Generic 18 $803
Triamcinolone Acetonide Generic 48 $773
Potassium Chloride Generic 21 $523
Doxycycline Hyclate Generic 75 $402
Atorvastatin Calcium Generic 50 $392
Levothyroxine Sodium Generic 40 $370

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$120,983

Of which drugs: $3,698

Medicare patients

233

Average age 77

Services billed

4,396

103 women, 130 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 39%
Diabetes 27%
Atrial fibrillation 18%
Ischemic heart disease 15%
Cancer 12%
COPD 11%
Osteoporosis 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 14 3,001 $3,631

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
  • Dermavant Sciences, Inc. $19
$19 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in Wyoming

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record